OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Role of Calcitonin Gene-Related Peptide on the Gastrointestinal Symptoms of Migraine—Clinical Considerations: A Narrative Review
Jessica Ailani, Eric A. Kaiser, Paul G. Mathew, et al.
Neurology (2022) Vol. 99, Iss. 19, pp. 841-853
Open Access | Times Cited: 37
Jessica Ailani, Eric A. Kaiser, Paul G. Mathew, et al.
Neurology (2022) Vol. 99, Iss. 19, pp. 841-853
Open Access | Times Cited: 37
Showing 1-25 of 37 citing articles:
CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond
Andrew F. Russo, Debbie L. Hay
Physiological Reviews (2022) Vol. 103, Iss. 2, pp. 1565-1644
Open Access | Times Cited: 162
Andrew F. Russo, Debbie L. Hay
Physiological Reviews (2022) Vol. 103, Iss. 2, pp. 1565-1644
Open Access | Times Cited: 162
A Scoping Review and Meta-Analysis of Anti-CGRP Monoclonal Antibodies: Predicting Response
Ja Bin Hong, Kristin Sophie Lange, Lucas Hendrik Overeem, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 7, pp. 934-934
Open Access | Times Cited: 44
Ja Bin Hong, Kristin Sophie Lange, Lucas Hendrik Overeem, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 7, pp. 934-934
Open Access | Times Cited: 44
The Interplay Between Gut Microbiota, Adipose Tissue, and Migraine: A Narrative Review
Valentina Biagioli, Federica Mela, Pietro Manuel Ferraro, et al.
Nutrients (2025) Vol. 17, Iss. 2, pp. 337-337
Open Access | Times Cited: 2
Valentina Biagioli, Federica Mela, Pietro Manuel Ferraro, et al.
Nutrients (2025) Vol. 17, Iss. 2, pp. 337-337
Open Access | Times Cited: 2
Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience
Bianca Raffaelli, Mira Pauline Fitzek, Lucas Hendrik Overeem, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 38
Bianca Raffaelli, Mira Pauline Fitzek, Lucas Hendrik Overeem, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 38
The sense of stopping migraine prophylaxis
Linda Al‐Hassany, Hannah Lyons, Deirdre M. Boucherie, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 30
Linda Al‐Hassany, Hannah Lyons, Deirdre M. Boucherie, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 30
Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan
Shiho Suzuki, Keisuke Suzuki, Tomohiko Shiina, et al.
Frontiers in Neurology (2023) Vol. 14
Open Access | Times Cited: 17
Shiho Suzuki, Keisuke Suzuki, Tomohiko Shiina, et al.
Frontiers in Neurology (2023) Vol. 14
Open Access | Times Cited: 17
Ten open questions in migraine prophylaxis with monoclonal antibodies blocking the calcitonin-gene related peptide pathway: a narrative review
Jean Schoenen, Annelies Van Dycke, Jan Versijpt, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 17
Jean Schoenen, Annelies Van Dycke, Jan Versijpt, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 17
Cardiovascular Adverse Drug Reactions of Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies for Migraine Prevention: An Analysis from the European Spontaneous Adverse Event Reporting System
Emanuela Elisa Sorbara, María Antonietta Barbieri, Giulia Russo, et al.
BioDrugs (2024) Vol. 38, Iss. 2, pp. 275-285
Closed Access | Times Cited: 6
Emanuela Elisa Sorbara, María Antonietta Barbieri, Giulia Russo, et al.
BioDrugs (2024) Vol. 38, Iss. 2, pp. 275-285
Closed Access | Times Cited: 6
The role of kynurenines in migraine-related neuroimmune pathways
Tamás Körtési, Gábor Nagy-Grócz, László Vécsei
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 6
Tamás Körtési, Gábor Nagy-Grócz, László Vécsei
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 6
Unmet Needs in the Acute Treatment of Migraine
Enrico Bentivegna, Silvia Galastri, Dilara Onan, et al.
Advances in Therapy (2023) Vol. 41, Iss. 1, pp. 1-13
Open Access | Times Cited: 14
Enrico Bentivegna, Silvia Galastri, Dilara Onan, et al.
Advances in Therapy (2023) Vol. 41, Iss. 1, pp. 1-13
Open Access | Times Cited: 14
Nutrition and Calcitonin Gene Related Peptide (CGRP) in Migraine
Michał Fila, Jan Chojnacki, Piotr Sobczuk, et al.
Nutrients (2023) Vol. 15, Iss. 2, pp. 289-289
Open Access | Times Cited: 11
Michał Fila, Jan Chojnacki, Piotr Sobczuk, et al.
Nutrients (2023) Vol. 15, Iss. 2, pp. 289-289
Open Access | Times Cited: 11
Effects of proton pump inhibitor (PPI) use on migraine – a critical review
Viktoria Tischler-Strasser, Irma Burdiladze, Gonçalo Cabral, et al.
The Journal of Headache and Pain (2025) Vol. 26, Iss. 1
Open Access
Viktoria Tischler-Strasser, Irma Burdiladze, Gonçalo Cabral, et al.
The Journal of Headache and Pain (2025) Vol. 26, Iss. 1
Open Access
Paralytic Ileus Following Long-term Erenumab Treatment
Shoji Kikui, Daisuke Danno, Takao Takeshima
Internal Medicine (2025)
Open Access
Shoji Kikui, Daisuke Danno, Takao Takeshima
Internal Medicine (2025)
Open Access
Calcitonin gene-related peptide-targeted therapy in migraine: current role and future perspectives
Jan Versijpt, Koen Paemeleire, Uwe Reuter, et al.
The Lancet (2025) Vol. 405, Iss. 10483, pp. 1014-1026
Closed Access
Jan Versijpt, Koen Paemeleire, Uwe Reuter, et al.
The Lancet (2025) Vol. 405, Iss. 10483, pp. 1014-1026
Closed Access
Unveiling the efficacy and safety of Erenumab, a monoclonal antibody targeting calcitonin gene-related peptide (CGRP) receptor, in patients with chronic and episodic migraine: a GRADE-assessed systematic review and meta-analysis of randomized clinical trials with subgroup analysis
Mohamed E. Haseeb, Hazem E. Mohammed, Hatem Yaser, et al.
Head & Face Medicine (2025) Vol. 21, Iss. 1
Open Access
Mohamed E. Haseeb, Hazem E. Mohammed, Hatem Yaser, et al.
Head & Face Medicine (2025) Vol. 21, Iss. 1
Open Access
A National Cross-Sectional Survey on Real-World Experiences of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody Use in Adults with Migraine in Finland
Cash Casey, Mari Pölkki, Elisa K Suvanen, et al.
Pain and Therapy (2025)
Open Access
Cash Casey, Mari Pölkki, Elisa K Suvanen, et al.
Pain and Therapy (2025)
Open Access
Sex Specific Effects of Environmental Toxin‐Derived Alpha Synuclein on Enteric Neuronal‐Epithelial Interactions
Hayley N. Templeton, Alexis Ehrlich, Luke Schwerdtfeger, et al.
Neurogastroenterology & Motility (2025)
Open Access
Hayley N. Templeton, Alexis Ehrlich, Luke Schwerdtfeger, et al.
Neurogastroenterology & Motility (2025)
Open Access
Evidence-based guidelines for the pharmacological treatment of migraine
Raffaele Ornello, Valeria Caponnetto, Fayyaz Ahmed, et al.
Cephalalgia (2025) Vol. 45, Iss. 4
Closed Access
Raffaele Ornello, Valeria Caponnetto, Fayyaz Ahmed, et al.
Cephalalgia (2025) Vol. 45, Iss. 4
Closed Access
Calcitonin Gene-Related Peptide Systemic Effects: Embracing the Complexity of Its Biological Roles—A Narrative Review
Adriano Bonura, Nicoletta Brunelli, Marilena Marcosano, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 18, pp. 13979-13979
Open Access | Times Cited: 9
Adriano Bonura, Nicoletta Brunelli, Marilena Marcosano, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 18, pp. 13979-13979
Open Access | Times Cited: 9
Efficacy and safety of atogepant, a small molecule CGRP receptor antagonist, for the preventive treatment of migraine: a systematic review and meta-analysis
Min Hou, Xiaofeng Luo, Shuangshuang He, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 3
Min Hou, Xiaofeng Luo, Shuangshuang He, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 3
Adverse events associated with Atogepant: a faers-based pharmacovigilance analysis
Ying Zhang, Shengzhu Sun, Y. Wang
Expert Opinion on Drug Safety (2024), pp. 1-7
Closed Access | Times Cited: 3
Ying Zhang, Shengzhu Sun, Y. Wang
Expert Opinion on Drug Safety (2024), pp. 1-7
Closed Access | Times Cited: 3
Persistence, effectiveness, and tolerability of anti‐calcitonin gene–related peptide monoclonal antibodies in patients with chronic migraine
Anna de Dios, Neus Pagès‐Puigdemont, Sergio R. Ojeda, et al.
Headache The Journal of Head and Face Pain (2024) Vol. 65, Iss. 1, pp. 24-34
Closed Access | Times Cited: 3
Anna de Dios, Neus Pagès‐Puigdemont, Sergio R. Ojeda, et al.
Headache The Journal of Head and Face Pain (2024) Vol. 65, Iss. 1, pp. 24-34
Closed Access | Times Cited: 3
Microbiome contributions to pain: a review of the preclinical literature
M. Pratt, Ashley N. Plumb, Aditi Manjrekar, et al.
Pain (2024)
Closed Access | Times Cited: 2
M. Pratt, Ashley N. Plumb, Aditi Manjrekar, et al.
Pain (2024)
Closed Access | Times Cited: 2
Could efficacy at 1 week after galcanezumab administration for patients with migraine predict responders at 3 months? A real world study
Keisuke Suzuki, Shiho Suzuki, Tomohiko Shiina, et al.
Journal of Neurology (2023) Vol. 270, Iss. 9, pp. 4377-4384
Closed Access | Times Cited: 5
Keisuke Suzuki, Shiho Suzuki, Tomohiko Shiina, et al.
Journal of Neurology (2023) Vol. 270, Iss. 9, pp. 4377-4384
Closed Access | Times Cited: 5
Consensus-Based Recommendations on the Use of CGRP-Based Therapies for Migraine Prevention in the UAE
Taoufik Alsaadi, Deeb Maxwell Kayed, Abubaker Almadani, et al.
Neurology and Therapy (2023) Vol. 12, Iss. 6, pp. 1845-1865
Open Access | Times Cited: 5
Taoufik Alsaadi, Deeb Maxwell Kayed, Abubaker Almadani, et al.
Neurology and Therapy (2023) Vol. 12, Iss. 6, pp. 1845-1865
Open Access | Times Cited: 5
